The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future

Microbes and Infection

Volumn 22, Issue 2, 2020, Pages 80-85

  Li, Jin Yan ^a   You, Zhi ^a   Wang, Qiong ^a   Zhou, Zhi Jian ^a   Qiu, Ye ^a   Luo, Rui ^b,c   Ge, Xing Yi ^a  

^a HUNAN UNIVERSITY   (China)

^b HUAZHONG AGRICULTURAL UNIVERSITY   (China)

^c THE COOPERATIVE INNOVATION CENTER FOR SUSTAINABLE PIG PRODUCTION   (China)

Author keywords

2019 nCoV; ACE2; Bat; Pneumonia; SARS CoV; Spike

Indexed keywords

ANTIVIRUS AGENT; VIRUS SPIKE PROTEIN; COVID-19; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS RECEPTOR;

2019 NOVEL CORONAVIRUS; ANTIVIRAL THERAPY; ARTICLE; CHINA; CLINICAL FEATURE; CORONAVIRIDAE; CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; EPIDEMIC; GENOMICS; HUMAN; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH; RECEPTOR BINDING; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRAL TROPISM; VIRUS IDENTIFICATION; VIRUS PNEUMONIA; VIRUS TRANSMISSION; BETACORONAVIRUS; COMMUNICABLE DISEASE; GENETICS; PATHOGENICITY; PHYLOGENY; VIROLOGY; VIRUS GENOME;

ANTIVIRAL AGENTS; BETACORONAVIRUS; CHINA; COMMUNICABLE DISEASES, EMERGING; CORONAVIRUS INFECTIONS; EPIDEMICS; GENOME, VIRAL; HUMANS; PHYLOGENY; PNEUMONIA, VIRAL; RECEPTORS, VIRUS; VIRAL TROPISM;

EID: 85081340190     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2020.02.002     Document Type: Article

References (44)

1. Cui, J., Li, F., Shi, Z.L., Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 17 (2019), 181–192.
2. Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:8 (2020), 727–733.
3. WHO. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
4. Chan, J.F., Yuan, S.F., Kok, K.H., To, K.K., Chu, H., Yang, J., et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 395:10223 (2020), 514–523.
5. Wang, C., Horby, P.W., Hayden, F.G., Gao, G.F., A novel coronavirus outbreak of global health concern. Lancet 395:10223 (2020), 470–473.
6. Chinese, C.D.C., http://2019ncov.chinacdc.cn/2019-ncov/.
7. Tatem, A.J., Rogers, D.J., Hay, S.I., Global transport networks and infectious disease spread. Adv Parasitol 62 (2006), 293–343.
8. Wu, J.T., Leung, K., Leung, G.M., Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet, 2020, 10.1016/S0140-6736(20)30260-9.
9. Cohen, J.N., Normile, D., New SARS-like virus in China triggers alarm. Science 367 (2020), 234–235.
10. Announcement from the Headquarter for novel coronavirus pneumonia prevention and control (No. 1), 2020, China National Health Commission, Beijing http://www.gov.cn/xinwen/2020-01/23/content_5471751.htm. (Accessed 23 January 2020)
11. Graham, R.L., Donaldson, E.F., Baric, R.S., A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol 11 (2013), 836–848.
12. Su, S., Wong, G., Shi, W.F., Liu, J., Lai, A.C., Zhou, J.Y., et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 24 (2016), 490–502.
13. Forni, D., Cagliani, R., Clerici, M., Sironi, M., Molecular evolution of human coronavirus genomes. Trends Microbiol 25 (2017), 35–48.
14. Lipsitch, M.C., Cohen, T., Cooper, B., Robins, J.M., Ma, S., James, L., et al. Transmission dynamics and control of severe acute respiratory syndrome. Science 300 (2003), 1966–1970.
15. Wallinga, J., Teunis, P., Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures. Am J Epidemiol 160 (2004), 509–516.
16. Lin, Q., Chiu, A.P., Zhao, S., He, D., Modeling the spread of Middle East respiratory syndrome coronavirus in Saudi Arabia. Stat Methods Med Res 27 (2018), 1968–1978.
17. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (2020), 497–506.
18. Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395 (2020), 507–513.
19. Chan, K.H., Peiris, J.S., Lam, S.Y., Poon, L.L., Yuen, K.Y., Seto, W.H., The effects of temperature and relative humidity on the viability of the SARS coronavirus. Adv Virol, 7, 2011, 734690.
20. Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020, 10.1038/s41586-020-2012-7.
21. Hoffmann, M., Kleine, W.H., Krüger, N., Müller, M., The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. 2020.
22. Zhao, Y., Zhao, Z.X., Wang, Y.J., Zhou, Y.Q., Ma, Y., Zuo, W., Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. 2020.
23. Zhang, H., Kang, Z.J., Gong, H.Y., Xu, D., Wang, J., Li, Z.F., et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. 2020.
24. Wu, F., Zhao, S., Bin, Y., Chen, Y.M., Wang, W., Song, Z.G., et al. A new coronavirus associated with human respiratory disease in China. Nature, 2020, 10.1038/s41586-020-2008-3.
25. Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, 2020, 10.1016/S0140-6736(20)30251-8.
26. Hu, B., Zeng, L.P., Yang, X.L., Ge, X.Y., Zhang, W., Li, B., et al. Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS Pathog, 13, 2017, e1006698.
27. Letko, M.M.V., Functional assessment of cell entry and receptor usage for lineage B β-coronaviruses, including 2019-nCoV. 2020.
28. Wan, Y., Shang, J., Graham, R., Baric, R.S., Li, F., Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol, 2020, 10.1128/JVI.00127-20.
29. Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med, 2020, 10.1056/NEJMoa2001316.
30. Zaki, A.M., van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D., Fouchier, R.A., Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367 (2012), 1814–1820.
31. Guan, Y., He, B.J., Liu, Y.Q., Zhuang, X.L., Zhuang, Z.X., Cheung, C.L., et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302 (2003), 276–278.
32. Ge, X.Y., Li, J., Yang, X.L., Chmura, A.A., Zhu, G., Epstein, J.H., et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503 (2013), 535–538.
33. Azhar, E.I., El-Kafrawy, S.A., Farraj, S.A., Hassan, A.M., Al-Saeed, M.S., Hashem, A.M., et al. Evidence for camel-to-human transmission of MERS Coronavirus. N Engl J Med 370 (2014), 2499–2505.
34. Kupferschmidt, K., The camel connection. Science 343 (2014), 1422–1425.
35. Chinese I. https://m.thepaper.cn/newsDetail_forward_5835114?from=groupmessage&isappinstalled=0.2020.
36. Emery, S.L., Erdman, D.D., Bowen, M.D., Newton, B.R., Winchell, J.M., Meyer, R.F., et al. Real-time reverse transcription-polymerase chain reaction assay for SARSassociated coronavirus. Emerg Infect Dis 10 (2004), 311–316.
37. Gaunt, E.R., Hardie, A., Claas, E.C., Simmonds, P., Templeton, K.E., Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol 48 (2010), 2940–2947.
38. Xu, Z.J., Peng, C., Shi, Y.L., Zhu, Z.D., Mu, K.J., Wang, X.Y., et al. Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. 2020.
39. Tai, D., Pharmacologic treatment of SARS: current knowledge and recommendations. Ann Acad Med Singapore 36 (2007), 438–443.
40. Chu, C.M., Cheng, V.C., Hung, I.F., Wong, M.M., Chan, K.H., Chan, K.S., et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 59 (2004), 252–256.
41. Nukoolkarn, V.L., Lee, V.S., Malaisree, M., Aruksakulwong, O., Hannongbua, S., et al. Molecular dynamic simulations analysis of ritonavir and lopinavir as SARSCoV 3CL(pro) inhibitors. J Theor Biol 254 (2008), 861–867.
42. Chong, Y.P., Song, J.Y., Seo, Y.B., Choi, J.P., Shin, H.S., Team, R.R., et al. Antiviral treatment guidelines for middle east respiratory syndrome. Infect Chemother 47 (2015), 212–222.
43. Arabi, Y.M., Alothman, A., Balkhy, H.H., Al-Dawood, A., c, S., Harbi, S.A., et al. Treatment of Middle East Respiratory Syndrome with a combination of lopinavirritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials, 19, 2018, 81.
44. Wang, M.L., Cao, R., Zhang, L., Yang, X.L., Liu, J., Xu, M.Y., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020.